Chinese Neurological Association, CMNN & ECF joint Symposium
The European Charcot Foundation, the Chinese Neurological Association and the Chinese Medical Network of Neuroinflammation are jointly organising a digital conference on "Multiple Sclerosis and related disorders" on Saturday September 19th and Sunday September 20th, 2020.
ECF, Chinese Neurological Association & CMNN joint Symposium "Multiple Sclerosis and related disorders"
Saturday 19 September 2020, 14:00 - 17:32, China Standard Time (UTC +8)
Chairs: prof Fu-Dong Shi & prof Giancarlo Comi
- 14:00 - 14:20 (UTC +8):
How to optimize treatment in relapsing remitting MS
Prof Dr Gilles Edan (Rennes, France)
- 14:20 - 14:40 (UTC +8):
MS treatment: looking to the future
Prof Dr Hans-Peter Hartung (Dusseldorf, Gemany)
- 14:40 - 15:00 (UTC +8):
Association of ABCG2 mutation with terifluramine exposure in relapsing MS patients for 24 weeks: research principle and design
- 15:00 - 15:08 (UTC +8):
Risk of COVID-19 infection in MS and neuromyelitis optic spectrum disease
- 15:08 - 15:16 (UTC +8):
Regulation of Kv1.3 pathway blocker on blood brain barrier in MS
- 15:16 - 15:24 (UTC +8):
Immunomodulatory mechanism of intraluminal rapamycin on Gas6 / TAM pathway in EAE mice
- 15:24 - 15:32 (UTC +8):
Therapeutic effect of DC induced by silencing MyD88 on EAE
- 15:32 - 16:00 (UTC +8):
- 16:00 - 16:20 (UTC +8):
From clinical trials to clinical practices in progressive MS
Prof Dr Giancarlo Comi (Milan, Italy)
- 16:20 - 16:40 (UTC +8):
A novel NMOSD mouse model based on reversible blood brain barrier opening technology
- 16:40 - 17:00 (UTC +8):
Long term efficacy of mycophenolate mofetil in treatment of myelin oligodendrocyte glycoprotein antibody-associated diseases: a prospective study
- 17:00 - 17:08 (UTC +8):
MRI features of intracranial lesions in patients with MOG antibody disease
- 17:08 - 17:16 (UTC +8):
Clinical characteristics and prognosis of MOG antibody associated encephalitis
- 17:16 - 17:24 (UTC +8):
A NMOSD mouse model based on low frequency ultrasound combined with microbubble Technology
- 17:24 - 17:32 (UTC +8):
Clinical characteristics of NF155 IgG positive patients in neuromyelitis optical spectrum diseases
Sunday 20 September 2020, 08:30 - 10:00 am (CST)
- 08:30 - 08:50 (UTC +8):
NMOSD: pathophysiological and clinical aspects
Prof Dr Kazuo Fujihara (Fukushima, Japan)
- 08:50 - 09:10 (UTC +8):
NMOSD treatment and monitoring
Prof Dr Fu-Dong Shi (Beijing, China)
- 09:10 - 09:30 (UTC +8):
Diagnosis and treatment strategy of "special population" in patients with NMOSD.
- 09:30 - 09:38 (UTC +8):
Efficacy and safety of reduced rituximab
in the treatment of NMOSD under B cell monitoring: a pilot study.
- 09:38 - 09:46 (UTC +8):
Immunotherapy for female NMOSD patients of childbearing age.
- 09:46 - 09:54 (UTC +8)
Intravenous immunogloblin in acute episode of NMOSD, an real world observation.
- 09:54 - 10:00 (UTC +8):
Association between basal ganglia, nucleus accumbens and fatigue in patients with NMOSD.